James S. Scibetta

Biography

Mr. Scibetta became a Director of Matinas BioPharma in November 2013. He is currently CEO of Maverick Therapeutics, a development stage immune-oncology company.  Prior to Maverick, he was President at Pacira Pharmaceuticals (Nasdaq: PCRX), where he oversaw global R&D, manufacturing and capacity expansion activities, as well as commercial and medical support activities. He joined Pacira as chief financial officer in 2008 and led the company's 2011 IPO and subsequent debt and equity financings. Prior to that, Mr. Scibetta was an executive with Bioenvision Inc. (Nasdaq: BIVN) a commercial stage oncology company acquired by Genzyme, and Merrimack Pharmaceuticals, an oncology-focused systems biology company. Earlier in his career he spent over a decade in investment banking where he was responsible for sourcing and executing transactions for a broad base of public and private healthcare and life sciences companies. He serves as a Board director and chairman of the audit committee of MonoSol Rx.  Mr. Scibetta received his Bachelor of Science in Physics from Wake Forest University and an MBA from the University of Michigan. 

Research Interest

Healthcare and life sciences